BMJ  1988;297:1017-1021 (22 October), doi:10.1136/bmj.297.6655.1017

Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.

Department of Gastroenterology, Glaxo Group Research Limited, Greenford, Middlesex.

OBJECTIVE: To evaluate the prophylactic effect of ranitidine 150 mg twice daily in patients requiring one of the following non-steroidal anti-inflammatory drugs: naproxen, piroxicam, diclofenac, and indomethacin. In addition, risk factors were studied in order to help in targeting of such treatment to specific groups of patients. DESIGN: Double blind, placebo controlled, randomised, parallel group with endoscopic assessments at 0, 4, and 8 weeks. SETTING: Multicentre outpatient study at secondary referral centres in five European countries. PATIENTS--297 patients with rheumatoid arthritis or osteoarthritis over the age of 18 without lesions in the stomach and duodenum at baseline endoscopy (after one week without taking non-steroidal anti-inflammatory drugs). Those taking other antirheumatic agents, concomitant ulcerogenic drugs, or treatment for peptic ulcers within the previous 30 days were excluded. Age, sex, arthritic disease, and type of non-steroidal anti-inflammatory drug used were comparable in the two treatment groups. In all, 263 patients completed the trial. INTERVENTIONS: Ranitidine 150 mg twice daily or placebo (plus the selected non-steroidal anti-inflammatory drug) was prescribed within five days after the baseline endoscopy for two consecutive periods of four weeks. Paracetamol was permitted during the study, but not antacids. Patients were withdrawn if the most severe grade of damage (including ulceration) was found at the four week endoscopy or when indicated, or with lesser damage at the investigator's discretion. END POINT: Frequency of gastric and duodenal ulceration or lesions, or both. MEASUREMENTS AND MAIN RESULTS: The cumulative incidence of peptic ulceration by eight weeks was 10.3% (27/263); 2 out of 135 (1.5%) developed duodenal ulceration in the ranitidine group, compared with 10 out of 126 (8%) taking placebo. The frequency of gastric ulceration was the same (6%) for the two groups at eight weeks. Though significantly fewer gastric lesions developed in the ranitidine group by eight weeks. The frequency of non-ulcerative lesions in the duodenum did not differ greatly for the two groups at either time point. Twelve out of 75 (16%) patients taking piroxicam developed peptic ulceration, of whom two thirds had duodenal ulceration. Patients with a history of peptic ulcer were particularly susceptible to recurrent ulceration, against which ranitidine offered some protection. CONCLUSIONS: Ranitidine 150 mg twice daily significantly reduced the incidence of duodenal ulceration but not gastric ulceration when prescribed concomitantly with one of four commonly used non-steroidal anti-inflammatory drugs.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

This article has been cited by other articles:

• Ong, C.K.S., Lirk, P., Tan, C.H., Seymour, R.A. (2007). An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. Clin Med Res 5: 19-34 [Abstract] [Full text]  
• Jacobsen, R. B, Phillips, B. B. (2004). Reducing Clinically Significant Gastrointestinal Toxicity Associated with Nonsteroidal Antiinflammatory Drugs. The Annals of Pharmacotherapy 38: 1469-1481 [Abstract] [Full text]  
• Setter, S. M., Corbett, C. F., Sclar, D. A., Gates, B. J., Johnson, S. B. (2001). Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Research to Help Your Patients Use them Safely. Home Health Care Management Practice 13: 468-475 [Abstract]  
• Jain, S., Datta, S., Tundis, D. (1999). Management of Chronic Postthoracotomy Pain. SEMIN CARDIOTHORAC VASC ANESTH 3: 191-203 [Abstract]  
• Koch, M., Dezi, A., Ferrario, F., Capurso, L. (1996). Prevention of Nonsteroidal Anti-inflammatory Drug--Induced Gastrointestinal Mucosal Injury: A Meta-analysis of Randomized Controlled Clinical Trials. Arch Intern Med 156: 2321-2332 [Abstract]  
• Singh, G., Ramey, D. R., Morfeld, D., Shi, H., Hatoum, H. T., Fries, J. F. (1996). Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid Arthritis: A Prospective Observational Cohort Study. Arch Intern Med 156: 1530-1536 [Abstract]  
• Soll, A. H., Practice Parameters Committee of the American Coll, , Achord, J. L., Bozymski, G., Brooks, S., Lanza, F., Lyon, D., Meyer, G., Reinus, J., Schuster, M., Achord, J., Ofman, J., Glassman, P., Laine, L., Tytgat, G., Walsh, J. H., Graham, D. Y., Peterson, W. L. (1996). Medical Treatment of Peptic Ulcer Disease: Practice Guidelines. JAMA 275: 622-629 [Abstract]  
• Griffin, M. R., Brandt, K. D., Liang, M. H., Pincus, T., Ray, W. A. (1995). Practical Management of Osteoarthritis: Integration of Pharmacologic and Nonpharmacologic Measures. Arch Fam Med 4: 1049-1055 [Abstract]  
• Ellershaw, J. E, Kelly, M. J (1994). Corticosteroids and peptic ulceration. Palliat Med 8: 313-319 [Abstract]  
• Wilcox, C. M., Shalek, K. A., Cotsonis, G. (1994). Striking Prevalence of Over-the-Counter Nonsteroidal Anti-inflammatory Drug Use in Patients With Upper Gastrointestinal Hemorrhage. Arch Intern Med 154: 42-46 [Abstract]  
• Feldman, M. (1993). Pros and Cons of Over-the-Counter Availability of Histamine2-Receptor Antagonists. Arch Intern Med 153: 2415-2424 [Abstract]  
• Levine, L. R., Cloud, M. L., Enas, N. H. (1993). Nizatidine Prevents Peptic Ulceration in High-Risk Patients Taking Nonsteroidal Anti-inflammatory Drugs. Arch Intern Med 153: 2449-2454 [Abstract]  
• Kaplan, B., Swain, R. A. (1993). NSAIDs: Are There Any Differences?. Arch Fam Med 2: 1167-1174 [Abstract]  
• Greene, J. M., Winickoff, R. N. (1992). Cost-Conscious Prescribing of Nonsteroidal Anti-inflammatory Drugs for Adults With Arthritis: A Review and Suggestions. Arch Intern Med 152: 1995-2002 [Abstract]  
• Cryer, B., Feldman, M. (1992). Effects of Nonsteroidal Anti-inflammatory Drugs on Endogenous Gastrointestinal Prostaglandins and Therapeutic Strategies for Prevention and Treatment of Nonsteroidal Anti-inflammatory Drug--Induced Damage. Arch Intern Med 152: 1145-1155 [Abstract]  
• Bloom, B. S. (1991). Cross-National Changes in the Effects of Peptic Ulcer Disease. ANN INTERN MED 114: 558-562 [Abstract]  
• Soll, A. H., Weinstein, W. M., Kurata, J., McCarthy, D. (1991). Nonsteroidal Anti-inflammatory Drugs and Peptic Ulcer Disease. ANN INTERN MED 114: 307-319 [Abstract]  
• Edelson, J. T., Tosteson, A. N. A., Sax, P. (1990). Cost-effectiveness of Misoprostol for Prophylaxis Against Nonsteroidal Anti-inflammatory Drug--Induced Gastrointestinal Tract Bleeding. JAMA 264: 41-47 [Abstract]  
• Hillman, A. L., Bloom, B. S. (1989). Economic Effects of Prophylactic Use of Misoprostol to Prevent Gastric Ulcer in Patients Taking Nonsteroidal Anti-inflammatory Drugs. Arch Intern Med 149: 2061-2065 [Abstract]  
• Bloom, B. S. (1989). Risk and Cost of Gastrointestinal Side Effects Associated With Nonsteroidal Anti-inflammatory Drugs. Arch Intern Med 149: 1019-1022 [Abstract]  

Online poll

Find out more on doc2doc >>